Premium
Reversible sideroblastic anemia associated with the tetracycline analogue COL‐3
Author(s) -
Rudek Michelle A.,
Horne McDonald,
Figg William D.,
Dahut William,
Dyer Valerie,
Pluda James M.,
Reed Eddie
Publication year - 2001
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.1076
Subject(s) - medicine , tetracycline , sideroblastic anemia , anemia , bone marrow , cancer , gastroenterology , oncology , biology , antibiotics , genetics
Eight of 35 patients with cancer receiving COL‐3, a tetracycline derivative with antiangiogenic properties, developed anemia while on treatment. All of these patients were enrolled on an approved Phase I clinical trial at the National Cancer Institute. Three of these patients had bone marrow examinations that revealed ringed sideroblasts. This paper describes these cases. Am. J. Hematol. 67:51–53, 2001. Published 2001 Wiley‐Liss, Inc.